RISE - Study of the AGN1 LOEP SV Kit in Patients With Vertebral Compression Fractures

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-19

Study Completion Date

2028-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, single-arm, multi-center, European clinical study designed to evaluate the clinical performance and safety of the AGN1 LOEP SV Kit for the treatment of painful VCFs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures

NCT04835428

Vertebral Compression Fracture Compression Fracture Vertebral Compression

RECRUITING NA

Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating

NCT02104167

Degenerative Disc Disease

COMPLETED

A Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

NCT01491425

Degenerative Disc Disease

COMPLETED NA

Patient Registry to Observe Outcomes Following Implantation of the VariLift Interbody Fusion Device

NCT01944345

Prolapsed Lumbar Disc Prolapsed Cervical Disc Intervertebral Disc Degeneration +2 more

COMPLETED

Retrospective/Prospective Data Collection on the LDR ROIA Interbody Fusion Device With VerteBRIDGE Plating

NCT02104141

Degenerative Disc Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A maximum of 100 subjects will be treated at up to 10 study sites across Europe. Follow up visits will be conducted at 1 day, 1 month, 3 months, 12 months and 24 months after the procedure.

Study enrollment will occur in three stages:

Stage 1: 5 subjects to evaluate safety at 3 months Stage 2: 30 subjects to evaluate safety at 3 months Stage 3: 100 subjects to evaluate safety and performance at 12 months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vertebral Compression Fracture Vertebral Compression Vertebral Fracture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment with AGN1 LOEP SV Kit

VCF is treated with the AGN1 LOEP SV Kit

Group Type EXPERIMENTAL

AGN1 LOEP SV Kit

Intervention Type DEVICE

The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AGN1 LOEP SV Kit

The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a male or female 50 years of age or older at time of study treatment.
2. Criterion omitted
3. Subject has only one (1) acute VCF. Subjects are eligible if they have an asymptomatic healed VCF at any non-target vertebral level.
4. This VCF meets all of the following criteria:

1. Fracture due to diagnosed or presumed underlying osteoporosis
2. VCF from T1 to L5 inclusive
3. Fracture age ≤6 months at time of treatment
5. Target VCF shows loss of height in the anterior or middle portion of the vertebral body of not more than 50% based on X-ray at baseline.
6. Target VCF is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI, bone scan, CT, serial radiographs, or other imaging demonstrating acuity.
7. Subject has central pain upon palpation over the spinal process at the target vertebral body.
8. Subject has failed conservative medical therapy, defined as either having a VAS back pain score of ≥ 70 mm after 24 hours to 6 weeks of conservative care or a VAS back pain score of ≥ 50 mm after 6 weeks of conservative care.
9. Subject has an Oswestry Disability Index (ODI) score of ≥ 30%.
10. Subject is capable of giving written informed consent to participate in the study.
11. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full length of the study has been documented.

Exclusion Criteria

1. Target VCF is due to underlying or suspected tumor.
2. Target VCF is due to high-energy trauma.
3. Target VCF is diagnosed as an osteonecrotic fracture.
4. Target VCF has segmental kyphosis of \> 30°.
5. Target VCF is unstable including split or burst fractures.
6. Subject has had any prior surgical treatment at the target VCF or adjacent vertebral level (above or below VCF).
7. Subject has neurologic symptoms, deficits, or radiculopathy related to the VCF.
8. Subject has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated.
9. Subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis).
10. Subject has spondylolisthesis \> Grade 1 at target vertebral body.
11. Subject has pain due to any other condition that requires daily narcotic medication.
12. Subject has severe cardiopulmonary deficiencies.
13. Subject has a bleeding disorder.
14. Subject has a Body Mass Index (BMI) \> 35.
15. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
16. Subject has a history of tuberculosis spondylitis.
17. Subject has a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for five (5) years.
18. Subject is on oral or parenteral immune-suppressive drugs.
19. Subject has an active bone infection at target VCF.
20. Subject has uncontrolled diabetes mellitus, as determined by the judgment of the Investigator.
21. Subject has severe renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \< 30 mL/min.
22. Subject has a diagnosed calcium metabolism disorder.
23. Subject has known allergies to calcium-based bone void fillers.
24. Subject is pregnant or planning to become pregnant during participation in the study.
25. In the judgment of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues).
26. Subject is currently enrolled in another interventional clinical study.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No